The PI3K{alpha} Inhibitor Alpelisib Has Activity in PIK3CA-altered Tumors [Clinical Trials]

The PI3Kα inhibitor alpelisib achieved a 58.2% disease control rate in PIK3CA-altered solid tumors.

from Cancer via ola Kala on Inoreader https://ift.tt/2pXQDnv
via IFTTT